Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study
Biopharmaceutics & Drug Disposition · 2023-04 · 44 (2) · 175-182
DOI: 10.1002/bdd.2354 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 28.03.2023. Verfasst von Liying Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: The key project plan for health and medical science research in Hebei Provincial Health Commission.
Abstract (Originalsprache)
Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti‐infectious efficacy. Compared with the low norvancomycin trough concentration group (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang, China.
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID-Profile: Xinran Chen
Förderung
- The key project plan for health and medical science research in Hebei Provincial Health Commission
Zitieren
APA
Du, L., Huo, L., Hou, J., Zhou, X., Liu, M., Guo, T., Wang, W., Chen, H., & Chen, X. (2023). Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition, 44(2), 175-182. https://doi.org/10.1002/bdd.2354
Vancouver
Du L, Huo L, Hou J, Zhou X, Liu M, Guo T, et al. Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition. 2023;44(2):175-182. doi:10.1002/bdd.2354
BibTeX
@article{Du2023,
author = {Du, Liying and Huo, Liman and Hou, Juan and Zhou, Xiajin and Liu, Mingfeng and Guo, Teng and Wang, Wei and Chen, Huihui and Chen, Xinran},
title = {Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
volume = {44},
number = {2},
pages = {175--182},
doi = {10.1002/bdd.2354}
}
EUVIMED